2024-05-22 13:32:00 ET
Summary
- Australia to ban compounded versions of Novo Nordisk's semaglutide and Eli Lilly's tirzepatide due to safety concerns.
- Existing home sales dipped 1.89% in April to 4.14 million.
- All eyes on Nvidia earnings but BofA points to another stock that deserves the title of AI darling.
Listen below or on the go on Apple Podcasts and Spotify
The health ministry cites adverse effects linked to compound versions. (0:16) Target falls on guidance . (2:44) The real AI boom darling (not Nvidia). (5:02)...
Read the full article on Seeking Alpha
For further details see:
Wall Street Lunch: Australia Bans Copycat Weight Loss Drugs